High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer

Lorena Rossi, Matteo Santoni, Simon J. Crabb, Emanuela Scarpi, Luciano Burattini, Caroline Chau, Emanuela Bianchi, Agnese Savini, Salvatore L. Burgio, Alessandro Conti, Vincenza Conteduca, Stefano Cascinu, Ugo De Giorgi

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Increased neutrophil-to-lymphocyte ratio (NLR), an index of systemic inflammation, is associated with poor outcome for various types of cancers. We assessed the role on outcome prediction of NLR at baseline and persistent during first-line chemotherapy in patients with advanced urothelial cancer. Methods: We retrospectively reviewed 292 patients with unresectable or metastatic urothelial cancer treated with first-line chemotherapy between January 2003 and December 2012. The cutoff values of NLR (>3 vs. 12 g/dL), pretherapy NLR (>3 vs. 3 vs. ≤3). Results: Patients with pre- and follow-up NLR of >3 had a median progression-free survival of 3.2 months and a median overall survival of 5.7 months. In multivariate analysis, visceral metastases, pretherapy hemoglobin, and follow-up NLR were significant predictors of progression-free survival [hazard ratio (HR) 1.75, P = 0.0001; HR 1.57, P = 0.0015; HR 2.77, P 

Original languageEnglish
Pages (from-to)1377-1384
Number of pages8
JournalAnnals of Surgical Oncology
Volume22
Issue number4
DOIs
Publication statusPublished - 2015

ASJC Scopus subject areas

  • Surgery
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer'. Together they form a unique fingerprint.

Cite this